These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 8739255)

  • 61. Therapeutic implications of beta-adrenergic receptor pharmacodynamic properties.
    Taira CA; Carranza A; Mayer M; Di Verniero C; Opezzo JA; Höcht C
    Curr Clin Pharmacol; 2008 Sep; 3(3):174-84. PubMed ID: 18781904
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Recent advances in cardiac beta(2)-adrenergic signal transduction.
    Xiao RP; Cheng H; Zhou YY; Kuschel M; Lakatta EG
    Circ Res; 1999 Nov; 85(11):1092-100. PubMed ID: 10571541
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Biologic rationale for the use of beta-blockers in the treatment of heart failure.
    Sabbah HN
    Heart Fail Rev; 2004 Apr; 9(2):91-7. PubMed ID: 15516856
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Beneficial effects of amiodarone in heart failure: interaction with beta-adrenoceptors rather than G proteins.
    Schnabel P; Mies F; Maack C; Rosenkranz S; Zolk O; Böhm M
    Eur J Pharmacol; 1999 Mar; 369(3):391-4. PubMed ID: 10225379
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Alteration of endothelin system and calcium handling protein in left ventricles following drug treatment in dilated cardiomyopathy rats.
    Zhang JN; Geng Q; Chen XJ; Fang WW; Wu XH; Yang D
    Acta Pharmacol Sin; 2003 Nov; 24(11):1099-102. PubMed ID: 14627492
    [TBL] [Abstract][Full Text] [Related]  

  • 66. beta 1-and beta 2-adrenergic receptors exhibit differing susceptibility to muscarinic accentuated antagonism.
    Aprigliano O; Rybin VO; Pak E; Robinson RB; Steinberg SF
    Am J Physiol; 1997 Jun; 272(6 Pt 2):H2726-35. PubMed ID: 9227552
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Improvement of cardiac function and beta-adrenergic signal transduction by propionyl L-carnitine in congestive heart failure due to myocardial infarction.
    Sethi R; Wang X; Ferrari R; Dhalla NS
    Coron Artery Dis; 2004 Feb; 15(1):65-71. PubMed ID: 15201623
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Alterations of beta-adrenoceptor-G-protein-regulated adenylyl cyclase in heart failure.
    Böhm M
    Mol Cell Biochem; 1995 Jun 7-21; 147(1-2):147-60. PubMed ID: 7494544
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Receptor systems affecting force of contraction in the human heart and their alterations in chronic heart failure.
    Brodde OE; Hillemann S; Kunde K; Vogelsang M; Zerkowski HR
    J Heart Lung Transplant; 1992; 11(4 Pt 2):S164-74. PubMed ID: 1355362
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Therapeutic options in the management of chronic heart failure. Is there a drug of first choice?
    Packer M
    Circulation; 1989 Jan; 79(1):198-204. PubMed ID: 2562938
    [No Abstract]   [Full Text] [Related]  

  • 71. [Drug therapy of congestive heart failure].
    Sasayama S
    Nihon Naika Gakkai Zasshi; 1997 Sep; 86(9):1770-7. PubMed ID: 9410998
    [No Abstract]   [Full Text] [Related]  

  • 72. Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.
    Van Tassell BW; Radwanski P; Movsesian M; Munger MA
    Pharmacotherapy; 2008 Dec; 28(12):1523-30. PubMed ID: 19025433
    [TBL] [Abstract][Full Text] [Related]  

  • 73. How do beta-blockers improve ventricular function in patients with congestive heart failure?
    Barry WH; Gilbert EM
    Circulation; 2003 May; 107(19):2395-7. PubMed ID: 12756189
    [No Abstract]   [Full Text] [Related]  

  • 74. Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats.
    Zolk O; Flesch M; Schnabel P; Teisman AC; Pinto YM; van Gilst WH; Paul M; Böhm M
    Br J Pharmacol; 1998 Feb; 123(3):405-12. PubMed ID: 9504380
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ca(2+)-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium.
    Movsesian MA; Karimi M; Green K; Jones LR
    Circulation; 1994 Aug; 90(2):653-7. PubMed ID: 8044934
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.
    Sethi R; Shao Q; Ren B; Saini HK; Takeda N; Dhalla NS
    Mol Cell Biochem; 2004 Aug; 263(1-2):11-20. PubMed ID: 15524163
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure.
    Brodde OE
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Feb; 374(5-6):361-72. PubMed ID: 17216434
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease.
    Castellano M; Böhm M
    Hypertension; 1997 Mar; 29(3):715-22. PubMed ID: 9052886
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.
    Bristow MR; Ginsburg R; Umans V; Fowler M; Minobe W; Rasmussen R; Zera P; Menlove R; Shah P; Jamieson S
    Circ Res; 1986 Sep; 59(3):297-309. PubMed ID: 2876788
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sarcoplasmic reticulum proteins in heart failure.
    Lehnart SE; Schillinger W; Pieske B; Prestle J; Just H; Hasenfuss G
    Ann N Y Acad Sci; 1998 Sep; 853():220-30. PubMed ID: 10603950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.